Influenced glimepiride metabolism by CYP2C9 inducers (eg, rifampicin) or inhibitors (eg, fluconazole). Potentiation of the blood glucose-lowering effect by insulin & other oral antidiabetics, ACE inhibitors, allopurinol, anabolic steroids, male sex hormones, chloramphenicol, coumarin derivatives, cyclophosphamide, disopyramide, fenfluramine, fenyramidol, fibrates, fluoxetine, guanethidine, ifosfamide, MAOIs, miconazole, fluconazole, aminosalicylic acid, pentoxifylline (high dose parenteral), phenylbutazone, azapropazone, oxyphenbutazone, probenecid, quinolones, salicylates, sulfinpyrazone, clarithromycin, sulfonamide antibiotics, tetracyclines, tritoqualine, trofosfamide. Weakening of the blood glucose-lowering effect by acetazolamide, barbiturates, corticosteroids, diazoxide, diuretics, epinephrine & other sympathomimetics, glucagon, laxatives (long-term use), nicotinic acid (high dose), oestrogens & progestogens, phenothiazines, phenytoin, rifampicin, thyroid hormones. May either potentiate or weaken effects w/ H
2 receptor antagonist, clonidine, guanethidine & reserpine, acute & chronic alcohol intake. Effect of coumarin derivatives may be potentiated or weakened. β-blockers decrease glucose tolerance. Reduced absorption w/ colesevelam. Metformin: Concomitant use w/ iodinated contrast materials, gentamicin. Weakened effect w/ epinephrine, pyrazinamide, INH. Increased plasma conc w/ furosemide, nifedipine & cationic drugs. May decrease anticoagulant effect of phenprocoumon. Reduced hypoglycemic effect w/ levothyroxine.